The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Caspases
/ drug effects
Down-Regulation
Drug Resistance, Neoplasm
/ drug effects
Drug Synergism
Fusion Proteins, bcr-abl
/ metabolism
Histone Deacetylase 6
/ antagonists & inhibitors
Humans
Imatinib Mesylate
/ pharmacology
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Mice
Mice, Inbred BALB C
Protein Kinase Inhibitors
/ pharmacology
Tumor Stem Cell Assay
Ubiquitination
/ drug effects
Xenograft Model Antitumor Assays
4-hydroxybenzoic acid
Cisplatin (PubChem CID: 441203)
Combination chemotherapy
Etoposide (VP-16, PubChem CID: 92209272)
Imatinib (PubChem CID: 123596)
Imatinib resistance
Leukemia stem cells
Suberanilohydroxamic acid (SAHA, PubChem CID: 5311)
Synergistic cytotoxic effect
Tubacin (PubChem CID: 6675804)
Tyrosine kinase inhibitor
Z-VAD-FMK (zVAD, PubChem CID: 5737)
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
10
11
2019
revised:
24
06
2020
accepted:
28
06
2020
pubmed:
4
7
2020
medline:
17
8
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
Despite the discovery of tyrosine kinase inhibitors (TKIs) for the treatment of breakpoint cluster region-Abelson (BCR-ABL)
Identifiants
pubmed: 32619722
pii: S1043-6618(20)31366-9
doi: 10.1016/j.phrs.2020.105058
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Fusion Proteins, bcr-abl
EC 2.7.10.2
Caspases
EC 3.4.22.-
HDAC6 protein, human
EC 3.5.1.98
Histone Deacetylase 6
EC 3.5.1.98
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105058Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.